We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Dings Pfizer China Facility Over Sample Retesting, cGMP Deviations
FDA Dings Pfizer China Facility Over Sample Retesting, cGMP Deviations
Pfizer’s Dalian, Liaoning, China, facility received a six-observation Form 483 for retesting failed samples, poor record controls and using an open pit for a urinal.